Apple adds more than £145bn to its value after unveiling largest share buyback in corporate history
Most parents think their children will be worse off than they are: Here's how to cut inheritance tax if you help them
'Mortgages at 2% aren't returning any time soon': As optimism over interest rate cuts this year fades, is a two-year fix still a good bet?
No Time To Buy: We reveal which film characters could ACTUALLY afford their car - and Bond's got some saving to do
Should you pay as much as possible into your pension? SIMON LAMBERT on the risk to early retirement dreams if the goalposts get moved
Britons cash in on gold price boom by selling it to the Royal Mint: How do you buy AND sell bars and coins... and what's the best way?
Hargreaves Lansdown will refund £100 in share dealing fees to customers - is it a deal worth taking?
The best buy-to-let mortgages for landlords: Should they fix or risk a tracker?
MARKET REPORT: Growth across Italy and Spain help Trainline post a big leap in annual sales and profits
Beware Labour tax secrets: What Rachel Reeves is not telling us, rather than public pronouncements, should alarm voters, says ALEX BRUMMER
Glencore plotting a takeover offer for Anglo American that would spark a bidding war with rival BHP
Shares in owner of make-up company Charlotte Tilbury lose their early shine on stock market debut
Competition watchdog sounds alarm over Pennon's takeover of Sutton and East Surrey Water
HSBC's chairman jeered by furious former staff who say bank is unfairly clawing back a chunk of their pensions
Spruce up your portfolio: Three Great British brands that could benefit from DIY boom
INVESTING EXPLAINED: What you need to know about primary listings - the stock market where a company's shares first went public
SHARE OF THE WEEK: BP shareholders looking for answers about planned transition away from fossil fuels with first quarter results
What are passkeys? Experts say they will replace 'unfit for purpose' passwords to keep your money and data safe online
Do I have to pay capital gains tax if I sell my bitcoin but don't take the cash out of my crypto account?
Shawbrook Bank didn't transfer my cash Isa and then paid just 0.1% interest for days - has it taken advantage of me?
We're financial experts - this is how you can use your Isa and pension to grow your wealth in the new tax year
My mortgage deal ends next year: Can I fix even if there is less than £20,000 left to pay off? DAVID HOLLINGWORTH REPLIES
The Bank of England must go it alone and cut interest rates, says ALEX BRUMMER: It's time to give business a huge confidence boost
'Change stamp duty so it's easier to move up and down housing ladder': Coventry Building Society joins calls for property tax reform

Daily Mail share tips: Adventis and Alexon

By This Is Money
Updated: 10:47 EDT, 25 September 2007

View
comments

Shares analysis from the Daily Mail's City team. The spotlight falls on advertising and marketing group Adventis and fashion chain Alexon.

Adventis

VITAL STATISTICS (full-year trading statement)
Pretax profit: £1.255m +57%
Dividend: 0.23p +5%
One-year share price performance: +54%

Advertising and marketing group Adventis is growing fast in its chosen fields - healthcare, financial services and property.

It advises top firms such as Pfizer and Glaxo on marketing drugs and Barclays, Standard Life and HBOS on pensions and insurance products. Its property clients include Savills, which owns a 32% stake.

Chief executive Charles Phillpot believes the healthcare side, bolstered by the £2.6m acquisition of Leapfrog Medical, has reached a credible size to serve the multinationals. He has his sights on a bigger acquisition. In such deals, at least half of the price is held back for future performance. He sees no sign of a slowdown, saying: 'Our clients are buoyant.'

Broker Arbuthnot expects full year profits of £2.5m to put the shares (up 3½p at 55½p) on 13 times earnings, falling to 11 times in 2008. The yield is 1.4pc.

VERDICT: Buy

Alexon

VITAL STATISTICS (full-year trading statement)
Pretax profit: £1.255m +57%
Dividend: 0.23p +5%
One-year share price performance: +54%

Advertising and marketing group Adventis is growing fast in its chosen fields - healthcare, financial services and property. It advises top firms such as Pfizer and Glaxo on marketing drugs and Barclays, Standard Life and HBOS on pensions and insurance products. Its property clients include Savills, which owns a 32% stake.

Chief executive Charles Phillpot believes the healthcare side, bolstered by the £2.6m acquisition of Leapfrog Medical, has reached a credible size to serve the multinationals.

He has his sights on a bigger acquisition. In such deals, at least half of the price is held back for future performance. He sees no sign of a slowdown, saying: 'Our clients are buoyant.'

Broker Arbuthnot expects full year profits of £2.5m to put the shares (up 3½p at 55½p) on 13 times earnings, falling to 11 times in 2008. The yield is 1.4%.

VERDICT: Buy

Some links in this article may be affiliate links. If you click on them we may earn a small commission. That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.